The CARLEN system departs from traditional transcatheter edge-to-edge repair techniques. Instead of employing sutures or tethers, the device augments the native mitral leaflet to restore coaptation while preserving natural leaflet motion and the valve's orifice area. This approach seeks to address limitations in patients with complex anatomy or underlying ventricular disease who may not be suitable candidates for current treatment options.

Following positive initial clinical experience, the ENHANCE study will track patients for five years to measure safety, procedural performance, and clinical endpoints. Early clinical sites include the University of São Paulo Hospital in Brazil and UC Davis Health in the United States. According to Lori Chmura, CEO of Nyra Medical, the study serves as a critical component of the company’s long-term strategy to expand treatment options for patients suffering from symptomatic moderate-to-severe or severe functional mitral regurgitation. Nyra plans to scale enrollment across additional structural heart centers as the global program progresses.